{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:16:37Z","timestamp":1791346597865,"version":"4.3.1"},"reference-count":123,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ymthe.2025.04.023","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:12:46Z","timestamp":1745233966000},"page":"2350-2362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical perspective: Advancing hemophilia treatment through gene therapy approaches"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-8958","authenticated-orcid":false,"given":"Courtney D.","family":"Thornburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cantore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Unzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheala","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-0061","authenticated-orcid":false,"given":"Wolfgang A.","family":"Miesbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.04.023_bib1","series-title":"StatPearls, (Treasure Island, FL)","article-title":"Hemophilia","author":"Mehta","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.023_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.04.023_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: A meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2025.04.023_bib5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/hae.14747","article-title":"Pain interferes with daily activities, emotions and sleep in adults with severe, moderate and mild haemophilia: A national cross-sectional survey","volume":"29","author":"Chantrain","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2025.04.023_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/hae.14926","article-title":"The psychosocial impact of haemophilia from patients' and caregivers' point of view: The results of an Italian survey","volume":"30","author":"Fornari","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2025.04.023_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/hae.14989","article-title":"Anxiety and depression among adults with haemophilia A: Patient and physician reported symptoms from the real-world European CHESS II study","volume":"30","author":"Ferri Grazzi","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2025.04.023_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/17474086.2023.2184341","article-title":"New directions to develop therapies for people with hemophilia","volume":"16","author":"Gogia","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib9","first-page":"221","article-title":"Recent advances in the treatment of hemophilia: A review","volume":"15","author":"Marchesini","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.ymthe.2025.04.023_bib10","article-title":"Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B","volume":"2","author":"Olasupo","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymthe.2025.04.023_bib11","article-title":"Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center","volume":"7","author":"Cohen","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.04.023_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/biom14070854","article-title":"Recent advances in gene therapy for hemophilia: Projecting the perspectives","volume":"14","author":"Chernyi","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2025.04.023_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1138596","article-title":"Immunogenicity of CRISPR therapeutics-Critical considerations for clinical translation","volume":"11","author":"Ewaisha","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib18","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib19","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib20","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1128\/JVI.75.6.2729-2740.2001","article-title":"Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses","volume":"75","author":"Lukashov","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.04.023_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10545-017-0053-3","article-title":"Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects","volume":"40","author":"Baruteau","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2025.04.023_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/hematology.2022000388","article-title":"Gene therapy for hemophilia","volume":"2022","author":"Nathwani","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ymthe.2025.04.023_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","article-title":"Adeno-associated virus (AAV) vectors in cancer gene therapy","volume":"240","author":"Santiago-Ortiz","year":"2016","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2025.04.023_bib26","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.04.023_bib27","series-title":"CRISPR\/Cas9-mediated Targeted Insertion of Human F9 Achieves Therapeutic Circulating Protein Levels in Mice and Non-human Primates","author":"Huang","year":"2019"},{"key":"10.1016\/j.ymthe.2025.04.023_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12111051","article-title":"Large-scale production of lentiviral vectors: Current perspectives and challenges","volume":"12","author":"Martinez-Molina","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2025.04.023_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2018.04.012","article-title":"Modulation of immune responses in lentiviral vector-mediated gene transfer","volume":"342","author":"Annoni","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147647","article-title":"Gene therapy in hemophilia: Recent advances","volume":"22","author":"Rodr\u00edguez-Merch\u00e1n","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.04.023_bib31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcyt.2024.09.001","article-title":"The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell engineering committee","volume":"27","author":"Oved","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2025.04.023_bib32","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood-2002-07-2314","article-title":"Side effects of retroviral gene transfer into hematopoietic stem cells","volume":"101","author":"Baum","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.023_bib33","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with fidanacogene elaparvovec in adults with hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib34","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib35","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","article-title":"Fidanacogene elaparvovec: First approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.04.023_bib37","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2025.04.023_bib38","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41467-022-28244-5","article-title":"CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations","volume":"13","author":"Hoijer","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.023_bib39","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.023_bib40","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ymthe.2020.03.015","article-title":"Variability in genome editing outcomes: Challenges for research reproducibility and clinical safety","volume":"28","author":"Teboul","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav7325","article-title":"Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates","volume":"11","author":"Milani","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib42","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s44321-024-00072-8","article-title":"GP64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia A mice","volume":"16","author":"Milani","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib43","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1038\/s41467-022-30102-3","article-title":"Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates","volume":"13","author":"Milani","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.023_bib44","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib45","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1172\/JCI37630","article-title":"The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy","volume":"119","author":"Montini","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.04.023_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa1405","article-title":"Liver-directed lentiviral gene therapy in a dog model of hemophilia B","volume":"7","author":"Cantore","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib47","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.023_bib48","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-024-08250-x","article-title":"Long-term lineage commitment in hematopoietic stem cell gene therapy","volume":"636","author":"Calabria","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.04.023_bib52","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa2410597","article-title":"Lentiviral gene therapy with cd34+ hematopoietic cells for hemophilia A","volume":"392","author":"Srivastava","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092319","article-title":"Induced pluripotent stem cells (iPSCs)-roles in regenerative therapies, disease modelling and drug screening","volume":"10","author":"Aboul-Soud","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2025.04.023_bib54","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/mt.2015.20","article-title":"Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib55","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1089\/hum.2018.137","article-title":"Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia A","volume":"29","author":"Doering","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib56","series-title":"StatPearls","article-title":"Busulfan","author":"Patel","year":"2025"},{"key":"10.1016\/j.ymthe.2025.04.023_bib57","series-title":"Encyclopedia of Toxicology","article-title":"Busulfan","author":"Janes","year":"2014"},{"key":"10.1016\/j.ymthe.2025.04.023_bib58","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2016.08.003","article-title":"In vivo tissue-tropism of adeno-associated viral vectors","volume":"21","author":"Srivastava","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib59","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/asheducation-2017.1.587","article-title":"Hemophilia gene therapy comes of age","volume":"2017","author":"George","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ymthe.2025.04.023_bib60","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/d41573-023-00103-y","article-title":"FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.04.023_bib61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ymthe.2017.12.007","article-title":"Hyperactive factor IX padua: A game-changer for hemophilia gene therapy","volume":"26","author":"VandenDriessche","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib62","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib63","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.04.023_bib64","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.04.023_bib65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.12412","article-title":"Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII","volume":"12","author":"Shahani","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.04.023_bib66","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib71","series-title":"Beqve","article-title":"Beqvez: Prescribing information","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.023_bib73","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib74","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.04.023_bib75","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41576-018-0068-0","article-title":"Publisher Correction: Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.04.023_bib76","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033583510000089","article-title":"The discovery of zinc fingers and their development for practical applications in gene regulation and genome manipulation","volume":"43","author":"Klug","year":"2010","journal-title":"Q. Rev. Biophys."},{"key":"10.1016\/j.ymthe.2025.04.023_bib78","article-title":"The role of recombinant AAV in precise genome editing","volume":"3","author":"Bijlani","year":"2021","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.ymthe.2025.04.023_bib79","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1182\/blood-2013-04-497354","article-title":"Robust ZFN-mediated genome editing in adult hemophilic mice","volume":"122","author":"Anguela","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.023_bib80","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.023_bib81","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","article-title":"First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I\/II and hemophilia B","volume":"30","author":"Harmatz","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.04.023_bib83","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jmb.2015.10.014","article-title":"Origins of programmable nucleases for genome engineering","volume":"428","author":"Chandrasegaran","year":"2016","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s43141-020-00078-y","article-title":"The genome editing revolution: review","volume":"18","author":"Khalil","year":"2020","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib86","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.04.023_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aao4774","article-title":"Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity","volume":"3","author":"Komor","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.04.023_bib88","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00439-017-1801-z","article-title":"CRISPR\/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice","volume":"136","author":"Huai","year":"2017","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymthe.2025.04.023_bib89","article-title":"Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.04.023_bib90","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-based therapeutic genome editing: Strategies and in vivo delivery by AAV vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.04.023_bib91","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1038\/s41467-022-34898-y","article-title":"Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody response","volume":"13","author":"He","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.023_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/v11010028","article-title":"Viral delivery systems for CRISPR","volume":"11","author":"Xu","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.04.023_bib93","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.12688\/f1000research.11243.1","article-title":"In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease","volume":"6","author":"Lau","year":"2017","journal-title":"F1000Res."},{"key":"10.1016\/j.ymthe.2025.04.023_bib94","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib95","series-title":"24th Annual Meeting of the American Society of Gene and Cell Therapy","article-title":"Avoiding Unintended Genome Editing for CRISPR\/Cas9 Therapeutics","author":"O'Connell","year":"2021"},{"key":"10.1016\/j.ymthe.2025.04.023_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2022.785698","article-title":"promoterless gene targeting approach combined to CRISPR\/Cas9 efficiently corrects hemophilia B phenotype in neonatal mice","volume":"4","author":"Lisjak","year":"2022","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.ymthe.2025.04.023_bib97","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/s41467-023-37465-1","article-title":"GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy","volume":"14","author":"Kasiewicz","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.023_bib98","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.04.023_bib99","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib100","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2023011847","article-title":"Roctavian gene therapy for hemophilia A","volume":"8","author":"Samelson-Jones","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.04.023_bib101","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.2022018971","article-title":"Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta study","volume":"143","author":"Leavitt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.023_bib102","series-title":"Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia \u0391: Primary Analysis Results from the Phase 3 \u0391FFINE Gene Therapy Trial","author":"Leavitt","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.023_bib103","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib104","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib105","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.023_bib106","unstructured":"U.S. Food and Drug Administration (2020). Human Gene Therapy for Rare Diseases. https:\/\/www.fda.gov\/media\/113807\/download."},{"key":"10.1016\/j.ymthe.2025.04.023_bib107","unstructured":"U.S. Food and Drug Administration (2020). Human Gene Therapy for Hemophilia. https:\/\/www.fda.gov\/media\/113799\/download."},{"key":"10.1016\/j.ymthe.2025.04.023_bib108","unstructured":"US Food and Drug Administration (2014). In Vitro Companion Diagnostic Devices. Guidance for Industry and Food and Drug Administration Staff. https:\/\/www.fda.gov\/media\/81309\/download."},{"key":"10.1016\/j.ymthe.2025.04.023_bib109","unstructured":"US Food and Drug Administration (2016). Principles for Codevelopment of an in Vitro Companion Diagnostic Device with a Therapeutic Product. https:\/\/www.fda.gov\/media\/99030\/download."},{"key":"10.1016\/j.ymthe.2025.04.023_bib110","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1089\/hum.2023.119","article-title":"Understanding and tackling immune responses to adeno-associated viral vectors","volume":"34","author":"Costa-Verdera","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib111","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.04.023_bib112","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib113","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.04.023_bib114","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib115","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1182\/blood-2010-09-306761","article-title":"Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection","volume":"117","author":"Biffi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.023_bib116","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.023_bib117","unstructured":"Be Biopharma. FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B. 2024. https:\/\/be.bio\/fda-grants-orphan-drug-designation-for-be-101-a-novel-engineered-b-cell-medicine-for-the-treatment-of-hemophilia-b\/."},{"key":"10.1016\/j.ymthe.2025.04.023_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15464","article-title":"CRISPR\/Cas9 targeting events cause complex deletions and insertions at 17 sites in the mouse genome","volume":"8","author":"Shin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.023_bib120","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nbt0918-899c","article-title":"Erratum: Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib121","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib122","doi-asserted-by":"crossref","first-page":"11264","DOI":"10.1073\/pnas.1117032109","article-title":"Induction of hepatocellular carcinoma by in vivo gene targeting","volume":"109","author":"Wang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.023_bib123","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.023_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007503","article-title":"No unexpected CRISPR-Cas9 off-target activity revealed by trio sequencing of gene-edited mice","volume":"14","author":"Iyer","year":"2018","journal-title":"Plos Genet."},{"key":"10.1016\/j.ymthe.2025.04.023_bib125","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1038\/s41467-018-05843-9","article-title":"Cas9 immunity creates challenges for CRISPR gene editing therapies","volume":"9","author":"Crudele","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.023_bib126","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.023_bib127","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/hae.14309","article-title":"Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre's readiness in United States and EU","volume":"27","author":"Miesbach","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2025.04.023_bib128","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/hae.14420","article-title":"Delivery of AAV-based gene therapy through haemophilia centres-A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC","volume":"27","author":"Miesbach","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2025.04.023_bib129","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2147\/PPA.S239810","article-title":"The patient experience of gene therapy for hemophilia: Qualitative interviews with trial patients","volume":"14","author":"Miesbach","year":"2020","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ymthe.2025.04.023_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100759","article-title":"Discussing investigational AAV gene therapy with hemophilia patients: A guide","volume":"47","author":"Sidonio","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.ymthe.2025.04.023_bib131","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/hae.13769","article-title":"How to discuss gene therapy for haemophilia? A patient and physician perspective","volume":"25","author":"Miesbach","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2025.04.023_bib132","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/hae.15100","article-title":"Development of the World Federation of Hemophilia Shared Decision-Making Tool","volume":"30","author":"Coffin","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2025.04.023_bib133","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/hae.15108","article-title":"A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results","volume":"30","author":"Hermans","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2025.04.023_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6050054","article-title":"Hemophilia care in the pediatric age","volume":"6","author":"Bertamino","year":"2017","journal-title":"J. Clin. Med."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:13:58Z","timestamp":1759612438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625002977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":123,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525001625002977"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.023","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical perspective: Advancing hemophilia treatment through gene therapy approaches","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}